Table of Contents

DSCAM Promotes Refinement in the Mouse Retina through Cell Death and Restriction of Exploring Dendrites

  1. Peter G. Fuerst1,4
  1. 1University of Idaho, Department of Biological Sciences, Moscow, Idaho 83844,
  2. 2Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44106,
  3. 3Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio 44195, and
  4. 4WWAMI Medical Education Program, Moscow, Idaho 83844
  1. Author contributions: P.G.F. designed research; S.L., J.M.S., A.B.S., E.J.H., I.S.S., and P.G.F. performed research; S.L., J.M.S., R.E.N., I.S.S., and P.G.F. analyzed data; I.S.S. and P.G.F. wrote the paper.

  2. ↵*S.L. and J.M.S. contributed equally to this work.

Abstract

In this study we develop and use a gain-of-function mouse allele of the Down syndrome cell adhesion molecule (Dscam) to complement loss-of-function models. We assay the role of Dscam in promoting cell death, spacing, and laminar targeting of neurons in the developing mouse retina. We find that ectopic or overexpression of Dscam is sufficient to drive cell death. Gain-of-function studies indicate that Dscam is not sufficient to increase spatial organization, prevent cell-to-cell pairing, or promote active avoidance in the mouse retina, despite the similarity of the Dscam loss-of-function phenotype in the mouse retina to phenotypes observed in Drosophila Dscam1 mutants. Both gain- and loss-of-function studies support a role for Dscam in targeting neurites; DSCAM is necessary for precise dendrite lamination, and is sufficient to retarget neurites of outer retinal cells after ectopic expression. We further demonstrate that DSCAM guides dendrite targeting in type 2 dopaminergic amacrine cells, by restricting the stratum in which exploring retinal dendrites stabilize, in a Dscam dosage-dependent manner. Based on these results we propose a single model to account for the numerous Dscam gain- and loss-of-function phenotypes reported in the mouse retina whereby DSCAM eliminates inappropriately placed cells and connections.

  • Received May 30, 2014.
  • Revision received February 18, 2015.
  • Accepted February 21, 2015.